A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Bladder Cancer
Unknown Primary
18 Years and older, Male and Female
CR109044 (primary)
NCI-2022-05645
17000139BLC2002
2020-005565-13
Summary
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination
with intravenous (IV) cetrelimab and IV cetrelimab alone.
Objectives
Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of
all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the
time of diagnosis, and roughly 50% will ultimately develop distant metastases. The TAR-200/
gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an
investigational drug. The drug constituent consists of gemcitabine minitablets and osmotic
minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa
monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The standard of
care in MIBC includes radical cystectomy (RC) with urinary diversion and is considered the
preferred treatment option for participants who are considered surgical candidates. Study
consists of a Screening phase, Treatment phase and follow-up phase. The total duration of
study will be up to 2 years and 6 months. Efficacy, safety, pharmacokinetics (PK), and
biomarkers will be assessed at specific time points during this study.
Eligibility
- Histologically proven, cT2-T4a N0, M0 infiltrating urothelial carcinoma of the bladder. Initial diagnosis must have been within 120 days of randomization date. Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial predominance. However, the presence of small cell or neuroendocrine variants will make a participant ineligible
- Participants with no residual tumor, or intravesical tumor size of less than or equal to (<=)3 centimeter (cm) following transurethral resection of bladder tumor (TURBT) are eligible; debulking TURBT for any residual disease is encouraged but not mandated. Participants with persistent tumors greater than (>)3 cm at screening must undergo a second debulking, re-staging TURBT. Participants will be ineligible if any individual tumor is >3 cm after debulking TURBT
- Deemed eligible for and willing to undergo RC by the operating urologist
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
- Thyroid function tests within normal range or stable on hormone supplementation per investigator assessment. Investigators may consult an endocrinologist for participant eligibility assessment in the case of equivocal or marginal tests results
- All adverse events associated with any prior surgery must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to randomization
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.